Browse TRAK1

Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Mitochondrion. Early endosome. Endosome. Note=Predominantly associated with early endosome. The localization to early endosomes depends on its interaction with HRS. Colocalizes with MGARP at the mitochondria.
Domain PF04849 HAP1 N-terminal conserved region
PF12448 Kinesin associated protein
Function

Involved in the regulation of endosome-to-lysosome trafficking, including endocytic trafficking of EGF-EGFR complexes and GABA-A receptors.

> Gene Ontology
 
Biological Process GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0007034 vacuolar transport
GO:0007041 lysosomal transport
GO:0008333 endosome to lysosome transport
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0016197 endosomal transport
GO:0043413 macromolecule glycosylation
GO:0070085 glycosylation
Molecular Function GO:0050811 GABA receptor binding
Cellular Component GO:0005769 early endosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-6802952: Signaling by BRAF and RAF fusions
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRAK1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRAK1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.64 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRAK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5360.0116
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1430.536
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0960.943
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5630.182
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7130.807
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3680.918
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0910.78
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1430.932
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0230.99
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3720.737
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2120.428
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0260.85
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRAK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRAK1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRAK1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRAK1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRAK1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRAK1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRAK1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRAK1
Nametrafficking protein, kinesin binding 1
Aliases OIP106; KIAA1042; MILT1; OGT(O Glc NAc transferase) interacting protein 106 KDa; O-linked N-acetylglucosamin ......
Chromosomal Location3p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRAK1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.